EA028062B1 - Лечение рака ингибиторами tor киназы - Google Patents

Лечение рака ингибиторами tor киназы Download PDF

Info

Publication number
EA028062B1
EA028062B1 EA201491701A EA201491701A EA028062B1 EA 028062 B1 EA028062 B1 EA 028062B1 EA 201491701 A EA201491701 A EA 201491701A EA 201491701 A EA201491701 A EA 201491701A EA 028062 B1 EA028062 B1 EA 028062B1
Authority
EA
Eurasian Patent Office
Prior art keywords
overexpression
castration
patient
prostate cancer
transcription factor
Prior art date
Application number
EA201491701A
Other languages
English (en)
Russian (ru)
Other versions
EA201491701A1 (ru
Inventor
Шуйчань Сюй
Шуйчань СЮЙ
Кристен Мей Хедж
Хитер Рэймон
Тосия Цудзи
Лиза Сапиносо
Original Assignee
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of EA201491701A1 publication Critical patent/EA201491701A1/ru
Publication of EA028062B1 publication Critical patent/EA028062B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201491701A 2012-03-15 2013-03-14 Лечение рака ингибиторами tor киназы EA028062B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611428P 2012-03-15 2012-03-15
US61/611,428 2012-03-15
US201261715327P 2012-10-18 2012-10-18
US61/715,327 2012-10-18
PCT/US2013/031217 WO2013138560A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201491701A1 EA201491701A1 (ru) 2015-01-30
EA028062B1 true EA028062B1 (ru) 2017-10-31

Family

ID=48045717

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491701A EA028062B1 (ru) 2012-03-15 2013-03-14 Лечение рака ингибиторами tor киназы

Country Status (21)

Country Link
US (1) US20130245028A1 (enExample)
EP (1) EP2825171B1 (enExample)
JP (2) JP2015511964A (enExample)
KR (1) KR102057357B1 (enExample)
CN (2) CN109846884A (enExample)
AU (2) AU2013202992B2 (enExample)
BR (1) BR112014022700A2 (enExample)
CA (1) CA2867174C (enExample)
EA (1) EA028062B1 (enExample)
ES (1) ES2668279T3 (enExample)
IL (1) IL234639B (enExample)
MX (1) MX359227B (enExample)
MY (1) MY198666A (enExample)
NI (1) NI201400110A (enExample)
NZ (1) NZ628420A (enExample)
PH (1) PH12014502047A1 (enExample)
SG (1) SG11201405686PA (enExample)
TW (1) TWI622395B (enExample)
UA (1) UA114194C2 (enExample)
WO (1) WO2013138560A1 (enExample)
ZA (1) ZA201406708B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
MX2015009209A (es) 2013-01-16 2016-03-17 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
EA030726B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
AU2014254059B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
CA2908353C (en) 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2908957C (en) * 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
HK1223286A1 (zh) 2013-05-29 2017-07-28 西格诺药品有限公司 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016210046A1 (en) * 2015-06-24 2016-12-29 Celgene Corporation Treatment of cancer with dnapk inhibitors
US11318139B2 (en) 2016-01-26 2022-05-03 Dana-Farber Cancer Institute, Inc. Methods for treating brain metastases using combinations of anti-P13K and anti-mTOR agents
ES2959860T3 (es) 2017-06-22 2024-02-28 Celgene Corp Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051494A1 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2008051493A2 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2010044893A1 (en) * 2008-10-17 2010-04-22 Merck & Co. Combination therapy
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2299474B1 (en) * 2008-07-10 2013-01-23 JX Nippon Mining & Metals Corporation Hybrid silicon wafer and method for manufacturing same
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
JP2012509058A (ja) * 2008-11-20 2012-04-19 オンコセラピー・サイエンス株式会社 前立腺癌を診断または治療するための方法
EP2430013B1 (en) * 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
NZ618135A (en) 2009-10-26 2015-05-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051494A1 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2008051493A2 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2010044893A1 (en) * 2008-10-17 2010-04-22 Merck & Co. Combination therapy
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A. M. SMITH, V. J. FINDLAY, S. G. BANDURRAGA, E. KISTNER-GRIFFIN, L. S. SPRUILL, A. LIU, A. R. GOLSHAYAN, D. P. TURNER: "ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype", CARCINOGENESIS, ¬IRL PRESS|, vol. 33, no. 3, 1 March 2012 (2012-03-01), pages 572 - 580, XP055061467, ISSN: 01433334, DOI: 10.1093/carcin/bgs007 *
EMMANUEL S. ANTONARAKIS, MICHAEL A. CARDUCCI, MARIO A. EISENBERGER: "Novel targeted therapeutics for metastatic castration-resistant prostate cancer", CANCER LETTERS, ELSEVIER, vol. 291, no. 1, 1 May 2010 (2010-05-01), pages 1 - 13, XP055062463, ISSN: 03043835, DOI: 10.1016/j.canlet.2009.08.012 *
H. WANG, C. ZHANG, A. RORICK, D. WU, M. CHIU, J. THOMAS-AHNER, Z. CHEN, H. CHEN, S. K. CLINTON, K. K. CHAN, Q. WANG: "CCI-779 Inhibits Cell-Cycle G2-M Progression and Invasion of Castration-Resistant Prostate Cancer via Attenuation of UBE2C Transcription and mRNA Stability", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 71, no. 14, 15 July 2011 (2011-07-15), pages 4866 - 4876, XP055062470, ISSN: 00085472, DOI: 10.1158/0008-5472.CAN-10-4576 *
LORI BERK; MONICA M. MITA; JEFF KREISBERG; CAMILLE L. BEDROSIAN; ANTHONY W. TOLCHER; TIM CLACKSON; VICTOR M. RIVERA: "Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 69, no. 5, 10 January 2012 (2012-01-10), Berlin, DE, pages 1369 - 1377, XP035047366, ISSN: 1432-0843, DOI: 10.1007/s00280-011-1813-7 *
MORGAN T M, KORECKIJ TD, COREY E.: "Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.", NIH PUBLIC ACCESS AUTHOR MANUSCRIPT, PUBLISHED IN FINAL EDITED FORM AS: CURR CANCER DRUG TARGETS. 2009 MARCH; 9(2):237-249., 1 March 2009 (2009-03-01), pages 1 - 24, XP002696902, DOI: 10.2174/156800909787580999 *
SCHAYOWITZ A, SABNIS G, GOLOUBEVA O, NJAR V C, BRODIE A M: "Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 103, no. 7, 28 September 2010 (2010-09-28), GB, pages 1001 - 1007, XP002696900, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6605882 *
SCHIEWER M J, DEN R, HOANG D T, AUGELLO M A, LAWRENCE Y R, DICKER A P, KNUDSEN K E: "mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer", ENDOCRINE - RELATED CANCER, BIOSCIENTIFICA LTD., GB, vol. 19, no. 1, 9 January 2012 (2012-01-09), GB, pages 1 - 12, XP002696901, ISSN: 1351-0088, DOI: 10.1530/ERC-11-0072 *

Also Published As

Publication number Publication date
BR112014022700A2 (pt) 2020-06-30
ZA201406708B (en) 2016-05-25
AU2013202992B2 (en) 2015-09-03
SG11201405686PA (en) 2014-10-30
AU2015213353B2 (en) 2017-07-27
UA114194C2 (uk) 2017-05-10
JP2015511964A (ja) 2015-04-23
HK1202247A1 (en) 2015-09-25
PH12014502047B1 (en) 2014-12-10
TW201343166A (zh) 2013-11-01
MY198666A (en) 2023-09-14
WO2013138560A1 (en) 2013-09-19
US20130245028A1 (en) 2013-09-19
MX2014011116A (es) 2015-04-08
NZ628420A (en) 2016-04-29
EP2825171A1 (en) 2015-01-21
JP2018058861A (ja) 2018-04-12
CA2867174A1 (en) 2013-09-19
CN109846884A (zh) 2019-06-07
NI201400110A (es) 2015-01-12
KR20140138928A (ko) 2014-12-04
MX359227B (es) 2018-09-20
CN104271138A (zh) 2015-01-07
IL234639B (en) 2020-05-31
AU2015213353A1 (en) 2015-09-03
IL234639A0 (en) 2014-11-30
EP2825171B1 (en) 2018-03-14
EA201491701A1 (ru) 2015-01-30
AU2013202992A1 (en) 2013-10-03
KR102057357B1 (ko) 2019-12-18
PH12014502047A1 (en) 2014-12-10
CA2867174C (en) 2020-06-23
ES2668279T3 (es) 2018-05-17
JP6470822B2 (ja) 2019-02-13
TWI622395B (zh) 2018-05-01

Similar Documents

Publication Publication Date Title
EA028434B1 (ru) Лечение рака ингибиторами tor киназы
EP3568204B1 (en) Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor
AU2013299841B8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
EA028414B1 (ru) Лечение рака ингибиторами tor киназы
JP2022034068A (ja) 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
CN113382774A (zh) 包含tno155和krasg12c抑制剂的药物组合
EA034512B1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
UA114194C2 (uk) Лікування раку інгібітором тоr кінази
Antonello et al. Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF
US20210322404A1 (en) Fgfr regulation for the treatment of viral infections
JP2009502960A (ja) 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
CN107207510B (zh) 联合疗法
JP2019048822A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
WO2014082085A1 (en) Use of itk inhibitors for the treatment of cancer
TW201909921A (zh) 治療組合
US20250339426A1 (en) Gcn2 modulator for treating cancer
US7947653B1 (en) Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
EP3167887B1 (en) Aryl amine substituted quinoxaline used as anticancer drugs
JP2024525515A (ja) がんの予防用又は治療用の医薬組成物
TW202146016A (zh) 投予抗癌劑之方法
CN120882412A (zh) 视黄醛脱氢酶1(raldh1)抑制剂和免疫刺激剂的组合及其使用方法
JP2019536771A (ja) エクソン１４スキッピング変異またはエクソン１４スキッピング表現型を有する癌の治療
US9763944B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
WO2025101914A1 (en) Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors having improved therapeutic index against solid tumors
TW202533828A (zh) Ａｋｔ抑制劑、ｂｃｌ－２抑制劑、及抗ｃｄ２０抗體之治療組合

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU